Shamburg News · 8-K filed Oct 9, 2026, 8:15 AM EDT
Atossa Therapeutics Executes Stapled CVR Agreement and Declares CVR Dividend
ATOS · ATOSSA THERAPEUTICS, INC.
- Material agreement
- Other event
- Other
- Materiality: high
On October 8, 2026, Atossa Therapeutics' Board declared a dividend of one stapled contingent value right per share of common stock outstanding at the close of business on October 19, 2026, and entered into a Stapled Contingent Value Rights Agreement with VStock Transfer, LLC as rights agent. The CVRs entitle holders, in the aggregate, to 25% of net proceeds from the sale or deemed monetization of the first qualifying FDA priority review voucher, subject to a $50 million cap and an outside date of December 31, 2036. No voucher has been awarded, and the company is under no obligation to develop or sell one.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.03, 8.01, 9.01, accession 0001193125-26-418560.
Written from the filing by Shamburg Markets. Figures are as reported by the company.